<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04104438</url>
  </required_header>
  <id_info>
    <org_study_id>Novartis18-000215</org_study_id>
    <nct_id>NCT04104438</nct_id>
  </id_info>
  <brief_title>Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant</brief_title>
  <official_title>A Study in Adults on Pre LT Dialysis With Basiliximab, Delayed Tacrolimus (TAC), Mycophenolate (MMF), Steroids (Grp 1) vs. Basiliximab, Delayed TAC, MMF, Steroids, With Everolimus 30d Post LT(Grp 2), vs. TAC, MMF, Steroids (Grp 3).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fady M Kaldas, M.D., F.A.C.S.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to help understand how well new combinations of immunosuppressive medications
      (medications that weaken your immune system to prevent your body from rejecting the
      transplanted liver) work compared to standard immunosuppressive medications after your liver
      transplant. Also the study will assess how safe the new combination of immunosuppressive
      medicines are and if there are any changes in how your kidneys work after taking these
      medicines.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single center, open label, randomized, prospective, pilot study of induction and
      maintenance immunosuppression in adult subjects &gt;18 years undergoing orthotopic liver
      transplantation (OLT) with Basiliximab, delayed dose tacrolimus plus mycophenolate mofetil
      and standard of care (SOC) corticosteroids (Group 1) versus basiliximab, delayed dose
      tacrolimus plus mycophenolate mofetil, SOC corticosteroids, with addition of delayed
      maintenance Everolimus at one month post OLT with subsequent mycophenolate mofetil
      minimization (Group 2) versus standard dose tacrolimus plus mycophenolate mofetil plus SOC
      corticosteroids (Group 3; control) with concomitant renal dysfunction prior to OLT.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>To assess the efficacy and safety of basiliximab, delayed dose tacrolimus plus mycophenolate mofetil, and SOC corticosteroids versus basiliximab, delayed dose tacrolimus plus mycophenolate mofetil, and SOC corticosteroids and addition of delayed everolimus/mycophenolate minimization at one month post OLT compared to standard triple immunosuppression (tacrolimus, mycophenolate mofetil and corticosteroids) for prevention of acute organ rejection in liver transplant recipients with a high risk of developing renal dysfunction following OLT or with concomitant renal dysfunction prior to OLT.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal Function</measure>
    <time_frame>6 months</time_frame>
    <description>Assessment of dialysis independence (patients no longer requiring dialysis post LT)</description>
  </primary_outcome>
  <other_outcome>
    <measure>cumulative allograft rejection</measure>
    <time_frame>6 months</time_frame>
    <description>rejection rate based on pathologic criteria</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Asses Immunosuppression Modulation on Renal Recovery Post LT</condition>
  <arm_group>
    <arm_group_label>Basiliximab with Delayed TAC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Basiliximab
Dose #1: 20mg IV within 2 hours of transplant
Dose #2: 20mg IV Post-operative day #4
Tacrolimus (with basiliximab induction) o Beginning day #5 post-transplant or when SCr &lt; 1.8 mg/dl (subjects off dialysis) to six months: 0.03-0.1mg/kg q12h PO to maintain whole blood trough concentration of 4-6ng/mL
Mycophenolate mofetil
o 1000 mg po bid
Corticosteroids (SOC): Per UCLA protocol
Post-operative taper:
Post-op day 1- methylprednisolone 50mg IVP Q6H
Post-op day 2- methylprednisolone 40mg IVP Q6H
Post-op day 3- methylprednisolone 30mg IVP Q6H
Post-op day 4- methylprednisolone 20mg IVP Q6H
Post-op day 5- methylprednisolone 20mg IVP Q12H
Post-op day 6- methylprednisolone 10mg IVP Q12H until taking PO, then change to: prednisone 20mg PO QAM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Basliximab, Delayed TAC with Everolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Basiliximab
Tacrolimus (with basiliximab induction)
o Beginning day #5 post-transplant or when SCr &lt; 1.8 mg/dl (subjects off dialysis) to POD 30: 0.03-0.1mg/kg q12h PO to maintain whole blood trough concentration of 4-6ng/mL
Mycophenolate mofetil o 1000 mg po bid up to POD 30: reduce mycophenolate mofetil following achievement of steady state everolimus (POD 35) as clinically indicated
Corticosteroids (SOC): Per UCLA protocol
Everolimus (delayed)
o Add by POD 30: 1 mg po bid and adjusted to maintain whole blood trough concentrations of 3-8 ng/ml.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control: standard TAC with steroids and MMF</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Tacrolimus (without basiliximab induction)
Beginning day #1 post-transplant to six months: 0.03-0.1mg/kg q12h po to maintain whole blood trough concentration of 5-12ng/mL
Six months to one year: maintain whole blood trough concentration of 5-10ng/mL
Mycophenolate mofetil
o 1000 mg po bid
Corticosteroids (SOC): Per UCLA protocol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Basiliximab 20 MG</intervention_name>
    <description>Basiliximab induction followed by tacrolimus, corticosteroids and mycophenolic acid with a switch to everolimus by post operative day 30</description>
    <arm_group_label>Basiliximab with Delayed TAC</arm_group_label>
    <arm_group_label>Basliximab, Delayed TAC with Everolimus</arm_group_label>
    <other_name>Everolimus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients eligible for inclusion in this study have to fulfill all of the following
             criteria:

               1. A signed informed consent prior to patient participation in the study and before
                  any assessment is performed.

               2. Patients who are able to take oral medication.

               3. 18 years old

               4. Undergoing first OLT

               5. Dialysis for 45 days or less at time of transplant

               6. Able and willing to conform to requirements of the study

               7. Able and willing to provide informed consent

                  Exclusion Criteria:

               1. &lt; 18 years old

               2. Autoimmune liver disease, Primary Sclerosing Cholangitis, Primary Biliary
                  Cirrhosis

               3. Dialysis greater than 45 days

               4. Receiving ATG, IVIG therapy, or sirolimus/everolimus around time of transplant or
                  sirolimus/everolimus after transplant

               5. Unable to take oral medications

               6. Participating in another clinical research study involving the evaluation of
                  another investigational drug or device

               7. Documented allergy to basiliximab, TAC, MMF or any macrolide antibiotic.

               8. Presence of thrombosis of any major hepatic arteries

               9. Complex/high risk arterial reconstruction at any time (graft vessel patency by
                  Doppler ultrasound confirmed and documented).

              10. Patients who are recipients of multiple solid organ transplants, (e.g.,
                  multivisceral or combined liver-kidney transplants), or have previously received
                  an organ or tissue transplanted, or who received an ABO incompatible transplant.

              11. Patients who have severe hypercholesterolemia (&gt;215 mg/dL; &gt;5.5 mmol/L) or
                  hypertriglyceridemia (&gt;265 mg/dL; &gt;3.0 mmol/L) at Baseline.

              12. Patients who have severe thrombocytopenia or neutropenia (platelet count &gt;20 and
                  MLCs&gt;1000)

              13. Patients who have any surgical or medical condition, which in the opinion of the
                  investigator, might significantly alter the absorption, distribution, metabolism
                  and excretion of study drugs

              14. Patients with a known hypersensitivity to the drugs used on study or their class,
                  or to any of the excipients.

              15. Patients with clinically significant systemic infection

              16. Pregnant or nursing (lactating) female patients, where pregnancy is defined as
                  the state of a female after conception and until the termination of gestation,
                  confirmed by a positive Î²HCG laboratory test (&gt;9 mIU/mL) at Baseline.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>78 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fady M Kaldas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA Dept Surgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fady M Kaldas, MD</last_name>
    <phone>310-825-5318</phone>
    <email>fkaldas@mednet.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Curtis D Holt, PharmD</last_name>
    <phone>310-206-4952</phone>
    <email>cholt@mednet.ucla.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 30, 2019</study_first_submitted>
  <study_first_submitted_qc>September 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2019</study_first_posted>
  <last_update_submitted>September 28, 2019</last_update_submitted>
  <last_update_submitted_qc>September 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Fady M Kaldas, M.D., F.A.C.S.</investigator_full_name>
    <investigator_title>Clincal Professor of Surgery</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Basiliximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

